These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
442 related items for PubMed ID: 26164066
1. Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. Preusser M, Berghoff AS, Koller R, Zielinski CC, Hainfellner JA, Liebmann-Reindl S, Popitsch N, Geier CB, Streubel B, Birner P. Eur J Cancer; 2015 Sep; 51(13):1803-11. PubMed ID: 26164066 [Abstract] [Full Text] [Related]
2. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Liu J, Liu Y. Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773 [Abstract] [Full Text] [Related]
5. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E. J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211 [Abstract] [Full Text] [Related]
6. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK. Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [Abstract] [Full Text] [Related]
7. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases. Allison DB, Lilo MT, Geddes S, Pallavajjalla A, Askin F, Gabrielson E, Zheng G, Li QK. Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084 [Abstract] [Full Text] [Related]
8. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics. Salimian KJ, Fazeli R, Zheng G, Ettinger D, Maleki Z. Acta Cytol; 2018 Jul; 62(2):79-84. PubMed ID: 29320776 [Abstract] [Full Text] [Related]
9. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing. El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, Benmokhtar S, Lamrani Alaoui H, El Annaz H, Abi R, Tagajdid MR, El Kochri S, El Mchichi B, Bouaiti EA, Lahlou IA, El Hassani RA, Ennibi K. Technol Cancer Res Treat; 2024 Jul; 23():15330338241288907. PubMed ID: 39363851 [Abstract] [Full Text] [Related]
10. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data. Zhao S, Cong X, Liu Z. Biomed Res Int; 2021 Jul; 2021():8817898. PubMed ID: 33997043 [Abstract] [Full Text] [Related]
11. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC. Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220 [Abstract] [Full Text] [Related]
12. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. Au CH, Wa A, Ho DN, Chan TL, Ma ES. Diagn Pathol; 2016 Jan 22; 11():11. PubMed ID: 26796102 [Abstract] [Full Text] [Related]
13. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, Kohonen-Corish MR, McCaughan BC, Trent RJ, Boyer MJ, Kench JG, Horvath LG, O'Toole SA. J Thorac Oncol; 2013 Apr 22; 8(4):408-14. PubMed ID: 23392229 [Abstract] [Full Text] [Related]
14. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Han G, Bi J, Tan W, Wei X, Wang X, Ying X, Guo X, Zhou X, Hu D, Zhen W. Oncotarget; 2016 Aug 30; 7(35):56998-57010. PubMed ID: 27486770 [Abstract] [Full Text] [Related]
15. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Thomas De Montpréville V, Ghigna MR, Lacroix L, Lemoine A, Besse B, Mercier O, Fadel É, Dorfmuller P, Le Chevalier T, Institut d’Oncologie Thoracique. Pathol Res Pract; 2017 Jul 30; 213(7):793-798. PubMed ID: 28554746 [Abstract] [Full Text] [Related]
16. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Int J Radiat Oncol Biol Phys; 2016 Oct 01; 96(2):406-413. PubMed ID: 27598807 [Abstract] [Full Text] [Related]
17. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. Shin SM, Cooper BT, Chachoua A, Butler J, Donahue B, Silverman JS, Kondziolka D. J Neurooncol; 2016 Feb 01; 126(3):483-91. PubMed ID: 26520640 [Abstract] [Full Text] [Related]